NCT05873686
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05873686
Title A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Nuvectis Pharma, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR

Facility Status City State Zip Country Details
Mayo Clinic Phoenix Arizona 85054 United States Details
UC San Diego Moores Cancer Center La Jolla California 92093 United States Details
Sarah Cannon Research Institute at HealthONE Denver Colorado 80218 United States Details
Mayo Clinic Jacksonville Florida 32224 United States Details
University of Chicago Chicago Illinois 60637 United States Details
Mayo Clinic Rochester Rochester Minnesota 55905 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10021 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
Oregon Health and Science University Portland Oregon 97239 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
NEXT Oncology Houston Houston Texas 77054 United States Details
NEXT Oncology Dallas Irving Texas 75039 United States Details
NEXT Oncology Virginia Fairfax Virginia 22031 United States Details
Western General Hospital - NHS Lothian Edinburgh EH4 2XU United Kingdom Details
The Royal Marsden NHS Foundation and Trust London SW3 6JJ United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field